RILPARENCEL
UNII B72T6TX3GS

Substance Identification & Data

This profile provides standardized clinical and technical data for Rilparencel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) B72T6TX3GS.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

B72T6TX3GS

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RILPARENCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190422

National Cancer Institute reference terminology for clinical and research data.

INN ID

12253

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-142

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Rilparencel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RILPARENCEL

Common Names & Synonyms

AUTOLOGOUS RENAL EPITHELIAL CELLS DERIVED FROM RENAL CORTICAL TISSUE VIA KIDNEY BIOPSY. THE CELLS ARE DISSOCIATED FROM THE KIDNEY BIOPSY USING ENZYMATIC DIGESTION AND THEN CULTURED IN MEDIUM SUPPLEMENTED WITH SEVERAL GROWTH FACTORS AND CYTOKINES, INCLUDING EPIDERMAL GROWTH FACTOR (EGF), HEPATOCYTE GROWTH FACTOR (HGF) AND INSULIN. PRIOR TO HARVESTING, CELLS ARE PLACED UNDER HYPOXIC CONDITIONS (2% OXYGEN). DENSITY GRADIENT IS USED TO SELECT THE DESIRED RENAL CELL POPULATION. THE FINAL CELL POPULATION EXPRESSES EPITHELIAL CELL MARKERS CYTOKERATIN 18 (CK18, >80%), GAMMA GLUTAMYL TRANSFERASE 1 (GGT1, >18%) AND CONTAINS A LOW PERCENTAGE OF OTHER RENAL CELL TYPES (AQUAPORIN 2 (AQP2), <=28%). THERE ARE FEW OR NO ENDOTHELIAL CELL PRESENT (LACK OF CD146 EXPRESSION). THE CELLS SECRETE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND DEMONSTRATE .GAMMA.-GLUTAMYL TRANSPEPTIDASE (GGT) AND LEUCINE AMINOPEPTIDASE (LAP) ENZYMATIC ACTIVITY

NEO KIDNEY AUGMENT (NKA)

RENAL AUTOLOGOUS CELL THERAPY (REACT)

RILPARENCEL [INN]

RILPARENCEL [USAN]

External Clinical & Regulatory Resources

Previous UNIIB72OSJ1JUX

Next UNIIB735YEI65V